Celcuity Inc. (CELC) Stock Score, Valuation & Financial Research

Celcuity Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CELC

Celcuity Inc. does not currently have a complete Wall Street Score. The stored market price is USD 67.51. These figures are a research snapshot, not a buy or sell recommendation.

What Celcuity Inc. does

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Celcuity is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of targeted oncology therapies, specifically its lead candidate gedatolisib, funded through capital raises and equity offerings until such time as a product may be commercialized.

Products and services

The company is developing gedatolisib, a kinase inhibitor targeting the PI3K/AKT/mTOR pathway for the treatment of solid tumors, including hormone receptor-positive (HR+), HER2-negative advanced breast cancer and metastatic castration-resistant prostate cancer.

Brands and product families

Gedatolisib — Lead therapeutic candidate currently in Phase 3 clinical trials. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial drug supplies. Source

Competitors and product-market comparisons

Pharmaceutical and biotechnology companies — Companies developing therapies for HR+/HER2- breast cancer and prostate cancer, including those targeting the PI3K/AKT/mTOR pathway. Source

Business strengths to evaluate

Breakthrough Therapy designation for gedatolisib Source

Business risks and research considerations

History of operating losses and dependence on additional financing Source
Clinical trial failure or regulatory rejection Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CELC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 67.51
Market capitalization:: 3.29B (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -226.48M
Free cash flow:: USD -153.53M
Cash:: USD 182.05M
Total debt:: USD 754.39M
EPS:: USD -4.29

What stands out

Free cash flow is USD -153.53M, negative for the stored period.
The balance sheet shows USD 182.05M of cash versus USD 754.39M of total debt, with debt exceeding cash on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Debt exceeds cash by USD 572.34M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CELC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can CELC fund negative free cash flow using its current cash position before it may need more debt or new shares?
Is CELC's debt load manageable relative to cash generation, interest costs and upcoming maturities?
What specifically needs to improve for CELC to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of CELC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CELC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.